Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 8/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13877230 | 0.84 | BCHE (0.55) | HTR6BCHEHRH1RAB9AKDM4E | |
| SCHEMBL7467529 | 0.82 | HTR6 (0.47) | HTR6BCHEHRH1PTGDR2TBXA2R | |
| Ammonia Solution, Strong SCHEMBL905721 | 0.80 | CA1 (0.63) | HTR6HRH1PABPC1RAB9AKDM4E | |
| SCHEMBL15899530 | 0.79 | HTR6 (0.55) | HTR6HRH1PABPC1RAB9AKDM4E | |
| SCHEMBL906131 | 0.78 | BCHE (0.53) | HTR6BCHEHRH1KDM4EPTGDR2 | |
| SCHEMBL8143242 | 0.77 | MAPT (0.52) | KDM4EHTT | |
| Ammonia Solution, Strong SCHEMBL905788 | 0.76 | RAB9A (0.40) | HTR6HRH1PABPC1RAB9AKDM4E | |
| SCHEMBL13877233 | 0.76 | ALOX5 (0.65) | HTR6BCHEHRH1 | |
| SCHEMBL12325728 | 0.76 | BCHE (0.45) | HTR6BCHEHRH1KDM4EPTGDR2 | |
| Ammonia Solution, Strong SCHEMBL905940 | 0.75 | RAB9A (0.44) | PABPC1RAB9AKDM4ENPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885BCHE 1192/4885HRH1 168/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885BCHE 1192/4885HRH1 168/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885BCHE 1192/4885HRH1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.